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investigator groupErratum
After publication of the original article [1], it came to
the authors’ attention that in the third paragraph of
the ‘Discussion’ section, the value of DAS28 in NEW
included patients is indicated wrongly, although
correctly cited in Table 2. The correct form of the
erroneous sentence is as follows:
“NEW patients´ median disease activity according
to the DAS28 before starting bDMARDs is in the
lower range in BIOREG compared to other European
bDMARD registries (4.46 compared to 4.2–6.6), while
median HAQ-DI scores are in a comparable range
(1.0 vs 0.8–1.9).”
To correct the original sentence, “(4.46 compared
to 4.2–6.6)” should be updated to “(4.13 compared to
4.2–6.6)”, and “in the lower range” should replace
“somewhat lower”.
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